

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15679 A2

(51) International Patent Classification⁷: **A61K 31/00**

D-14195 Berlin (DE). SCHUBERT, Gerd [DE/DE];
Kaethe-Kollwitz-Strasse 13, D-07753 Jena (DE).

(21) International Application Number: PCT/US00/23770

(22) International Filing Date: 31 August 2000 (31.08.2000)

(74) Agents: SOPP, John, A. et al.; Millen, White, Zelano &
Branigan, P.C., Arlington Courthouse Plaza 1, Suite 1400,
2200 Clarendon Boulevard, Arlington, VA 22201 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/386,141 31 August 1999 (31.08.1999) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/386,141 (CIP)
Filed on 31 August 1999 (31.08.1999)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*):
SCHERING AKTIENGESELLSCHAFT [DE/US];
D-13342 Berlin (DE). JENAPHARM GMBH & CO.
KG [DE/DE]; Otto-Schott-Strasse 15, D-07745 Jena (DE).

Published:

— Without international search report and to be republished
upon receipt of that report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CHWALISZ,
Kristof [DE/DE]; Lobber Steig 7a, D-13505 Berlin
(DE). ELGER, Walter [DE/DE]; Schorlemerallee 12B,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MESOPROGESTINS (PROGESTERONE RECEPTOR MODULATORS) FOR THE TREATMENT AND PREVEN-
TION OF BENIGN HORMONE DEPENDENT GYNECOLOGICAL DISORDERS

(57) Abstract: This present invention disclosed the use of mesoproggestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoproggestin. Mesoproggestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. The daily dose of mesoproggestin is 0.5 to 100 mg, preferably 5.0 to 50 mg and most preferably 10 to 25 mg. J867, J912, J956 and J1042 are the mesoproggestins preferred according to the invention.

WO 01/15679 A2

Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders

This invention relates to the treatment and prevention of major benign hormone dependent gynecological disorders, including the proliferative conditions such as endometriosis, uterine fibroids and postoperative peritoneal adhesions, as well as menstrual syndromes, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea.

Classically, these disorders are treated with medium or high dose progestins. This treatment, which efficacy is sometimes variable, is, however, associated with undesirable side-effects, including metabolic changes (increase in LDL and decrease in HDL concentrations), effects on mood, and breakthrough bleeding.

More recently, competitive progesterone receptor antagonist (antiprogestins), including onapristone, RU 486 (mifepristone), have been proposed as a novel approach for the treatment of endometriosis and dysmenorrhea (EP 0 266 303 B1), uterine fibroids [Yen SSC (1993) Use of antiprogestins in the management of endometriosis and leiomyomata. In Donaldson, M.s., Dorflinger (eds). Clinical application of Mifepristone (RU 486) and other antiprogestins. National Academy Press, Washington, DC, pp. 189-209; Kettel L.M., Murphy A.A., Morales A.J. et al., (1996) Treatment of endometriosis with the antiprogesterone mifepristone (RU 486). Fertil Steril 65: 23-28], and uterine bleeding disorders (WO 96/23503).

A potential drawback of antiprogestins is that their misuse for abortion cannot be ruled out completely.

Endometriosis

Endometriosis is a chronic disease characterized by ectopic growth of the endometrium, i.e. outside of the uterine cavity. The exact overall incidence of endometriosis is not known despite efforts to estimate how frequently it occurs and to fix the rates of occurrence in specific clinical situations (6,8,9,11). The figures range from 5% to 55%. The disease is characterized by histologically benign proliferation and function of the endometrial glands and stroma outside of their physiological location.

The ovary is the most common site of endometriosis (50-60%). Other commonly affected areas are: the uterosacral ligaments, cul-de-sac, uterovesical peritoneum, retrovaginal septum, and uterine ligaments. The endometriotic lesions may also be found on the organs, including the sigmoid colon, appendix, rectum, bladder, etc.

Endometriosis must be viewed as a disease of varying severity which frequently occurs in association with infertility and with significant dysfunction of pelvic pain. The clinical symptoms of endometriosis include dysmenorrhea, dyspareunia, chronic pelvic pain, dysuria, various genitourinary symptoms secondary to urethral obstruction and/or bladder invasion, painful defecation, rectal pressure, defecation urgency and bowel obstruction, bleeding abnormalities, including menorrhagia or metrorrhagia, infertility, primary or secondary, recurrent spontaneous abortions,

The major clinical symptoms are primary or acquired dysmenorrhea, dyspareunia and pelvic pain, especially in the ovulatory period.

The basic goals of medical therapy of endometriosis are to produce atrophy of endometriotic lesions and induce an acyclic hormone environment using GnRH-agonists/ – antagonists or continuous progestin treatment. Generally, these treatments produce a hypoestrogenic environment leading to the improvement of the disease.

The most frequently used progestins for medical therapy of endometriosis are danazol and gestrinone. Danazol is isoxazole derivative of 17-ethinyl testosterone with pronounced androgenic partial activity. Gestrinone is a derivative of 19-nortestosterone with potent gestagenic and androgenic properties. It has some advantages over danazol like less frequent administration, better contraceptive protection, and less influence on lipid metabolism. Danazol, the most widely used progestin is widely believed to act by suppressing cyclical gonadotrophin secretion, but there is growing evidence that this compound displays a multiple mechanism of action, including a direct inhibition of ectopic endometrial tissue. Treatment with danazol is associated with pronounced side effects. As many as 85% of women treated with danazol have side effects (67,68) such as: androgenic and anabolic changes (acne and oily skin, deepening of the voice, weight increase, increased LDL and decreased HDL concentrations, other side effects like edema, hypertension due to the glucocorticoid and mineralocorticoid partial activity of danazol, and intermenstrual bleeding.

Pituitary suppression can be achieved with GnRH-agonists and GnRH-antagonists. Different GnRH-agonists are currently used in treating endometriosis. This therapeutic regimen induces a profound hypoestrogenic, acyclic environment without exerting steroidal side effects. GnRH-analogs are effective in the treatment of endometriosis. Subjective and objective effects of this treatment are comparable to or even better than those of danazol (72-77). Signs and symptoms due to estrogen deprivation (hot flushes, psychic alternations, headache, tiredness, etc.) are the major side effects. In addition, GnRH-analogs therapy can induce osteoporosis (76,77). The possibility of accelerated bone loss during GnRH-analogs induced ovarian suppression is the major concern of an otherwise effective therapy for endometriosis.

In the meantime different add back regimes have been contemplated to substitute the estrogen suppression during GnRH-treatment by a selective estrogen receptor modulator (SERM) like raloxifene (SAG: WO 97/27863; Eli Lilly).

Menorrhagia

Menorrhagia is defined as menstrual bleeding >80 ml per period, a syndrome of unknown origin, is one of the most common problems in gynecology. 60% of women referred with menorrhagia have a hysterectomy within five years. The current medical treatment remains still unsatisfactory. The most commonly prescribed drug in Europe for an acute treatment during menstruation is norethisterone (~40%), followed by the nonsteroidal antiinflammatory drug (NSAID) mefenamic acid (~30%) and the antifibrinolytic drug tranexamic acid (5%) (Intercontinental Medical Statistics 1994). The last compound seems to be most effective in women with ovulatory menorrhagia (blood loss reduction by 45%) after acute administration during bleeding. Recently, the levonorgestrel intrauterine system (Mirena) has been introduced for the prevention of menorrhagia. A recent study has shown that both the levonorgestrel intrauterine system (Mirena) and oral norethisterone administered at a dose of 5 mg three times daily from day 5 to 26 of the cycle for three cycles provided an effective treatment (prevention) of menorrhagia in term of reducing to within normal limits. However, both treatment regimens were associated with high level of intermenstrual bleeding (50% of women treated with Mirena and 36% receiving norethisterone) (Irvine et al., 1998).

Dysmenorrhea

Dysmenorrhea is caused by painful uterine contractions. Women with dysmenorrhea have higher intrauterine resting and peak pressures when compared to normal controls. The exact mechanism of pain in dysmenorrhea is still unclear. Dysmenorrhea is most likely caused by increased uterine contractions and basal tone as well as a vasoconstriction of the spiral arteries during menstruation (Pickels et al., 1965; Csapo et al., 1977). Prevention of both uterine contractions and vasoconstriction of uterine vessels should, therefore, provide a relief of perimenstrual pain. Dysmenorrhea can be classified as primary or secondary dysmenorrhea (Dawood 1985; 1990). In primary dysmenorrhea there are painful menstrual cramps but no visible pelvic pathology to account for them. In secondary dysmenorrhea, however, there is visible pelvic pathology (e.g. endometriosis) which causes the painful menstrual cramps.

Primary dysmenorrhea is one of the most frequent gynecologic complains and affects as many as 50% of postpubercent females (Dawood 1985; 1990). With the availability of oral contraceptives and NSAIDs, both of which relieve primary dysmenorrhea effectively, the apparent prevalence rate may in fact be somewhat lower. Ten percent of women with primary dysmenorrhea have severe pain to render them incapacitated for 1 to 3 days each month, a situation leading to significant absenteeism (Svennerud, 1959) and consequent economic loss (Dawood 1985). Dysmenorrhea is therefore a significant medical and economic problem and better (simpler, safer) treatment can reduce the burden of disease to women and society.

Primary dysmenorrhea appears to be a single disease entity while secondary dysmenorrhea can be caused by a variety of disorders, including endometriosis and uterine fibroids. In general the treatment for primary dysmenorrhea is medication, whereas secondary dysmenorrhea usually requires surgical therapy for the underlying pathology (exceptions: secondary dysmenorrhea caused by the presence of an IUDs and endometriosis). Primary dysmenorrhea is most prevalent among young women in their teens or early twenties, declining again after the age of 30 (Widholm, 1979). Primary dysmenorrhea can be diagnosed on the basis of medical history and clinical features, physical examination and transvaginal ultrasound scan to exclude uterine abnormalities (Dawood, 1990).

Combined OCs and NSAIDs are widely used for prevention or treatment of perimenstrual pain. Both medications are effective in about 80-90% women with primary dysmenorrhea [Dawood, 1990]. However, 10-20% women with severe primary dysmenorrhea are resistant

to any treatment. In Germany ibuprofen (Urem[®], Gynofug[®]) is the most popular NSAID in dysmenorrhea. However, not all women/girls with primary dysmenorrhoea wish to take OCs or can tolerate NSAIDs treatment. This is the case particularly with girls between 13-16. Alternative medical therapy employs tocolytic drugs such as calcium channel blockers (Sandah et al., 1979) or betamimetics (Dawood, 1990). These act by suppressing uterine contractions but have not been found to be acceptable to patients, gynecologists and general physicians on a larger scale. The same applies to the progesterone releasing IUS. Transcutaneous electrical nerve stimulation (TENS) has been found to be only 30% effective in women with severe dysmenorrhea (Lundberg et al., 1985).

Therefore better tolerated and/or more accepted strategies to treat the aforementioned conditions are highly desirable.

This invention discloses the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders.

One aspect of the invention is the use of mesoprogestins for the manufacture of medicaments for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea.

Another aspect of the invention is the use of mesoprogestins for the manufacture of medicaments for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea.

Another aspect of the instant invention refers to the treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoprogestin.

Yet another aspect of the invention is the use of a daily dose of 0.5 to 100 mg mesoprogestin for treatment of the mentioned conditions.

More preferred is a daily dose of 5.0 to 50 mg mesoprogestin and most preferred is a daily dose of 10 to 25 mg of a mesoprogestin.

As mesoprogestins i.a. compounds disclosed in DE 43 32 283 and in DE 43 32 284 are suitable for the purposes of the invention.

As mesoprogestins are preferred the compounds J 867, J 912, J 900, J 914 and J 956 [J 867 [4-[17 β -Methoxy-17 α -(methoxymethyl)-3-oxoestra-4,9-dien-11 β -yl]benzaldehyd-(1E)-oxim] and J 912 [4-[17 β -Hydroxy-17 α -(methoxymethyl)-3-oxoestra-4,9-dien-11 β -yl]benzaldehyd-(1E)-oxim] (both DE 43 32 283) and J 900 [4-[17 β -Methoxy-17 α -(methoxymethyl)-3-oxoestra-4,9-dien-11 β -yl]benzaldehyd-(1E)-[O-(ethoxy)carbonyl]oxim], J 914 [4-[17 β -Methoxy-17 α -(methoxymethyl)-3-oxoestra-4,9-dien-11 β -yl]benzaldehyd-(1E)-(O-acetyl)oxim] and J 956 [4-[17 β -Methoxy-17 α -(methoxymethyl)-3-oxoestra-4,9-dien-11 β -yl]benzaldehyd-(1E)-[O-(ethylamino)carbonyl]oxim] (all DE 43 32 284) and J1042 [4-[17 β -Methoxy-17 α -(methoxymethyl)-3-oxoestra-4,9-dien-11 β -yl]benzaldehyd-(1E)-[O-(ethylthio)carbonyl]oxim (German Patent Application 198 09 845.6)] for the treatment and prevention of the above mentioned conditions as well as mesoprogesterin component in the pharmaceutical compositions and combinations mentioned thereafter which can also be used for treatment and prevention of the above mentioned conditions.

J 867 is described in DE 43 32 283 and J 900 and 914 are described in DE 43 32 284 as well as in corresponding patent applications as compounds having strong antiprogestagenic and compared to RU 486 having markedly reduced antiglucocorticoid activity. Moreover these compounds are mentioned to have (indirect) antiestrogenic properties reflected by reduced uterine weights in cyclic guinea pigs.

These effects should promise the exertion of a particularly favorable influence on pathologically modified tissues in which estrogens stimulate growth (endometriotic focuses, myomas, etc.) but it is not said expressis verbis that just the described compounds should be suitable in these indications. Also, the mentioned applications are silent about any active dose to be used to treat the mentioned conditions.

A progestagenic activity of the compounds disclosed is not mentioned in these applications at all.

According to the invention mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. As progestins and antiprogestins, mesoprogestins show high binding affinity to PR. However, mesoprogestins exhibit different pharmacodynamic properties compared to either progestins or antiprogestins. The presence of progesterone agonistic activity in mesoprogestins

measured in commonly used biological tests in vivo represents the key property of this novel class of PRMs. This activity remains, however, below that of progesterone in the plateau of the dose response curve. Mesoprogestins fail to maintain pregnancy in ovariectomized pregnant rodents as mice and rats.

In the classical bioassay, the McPhail test, assessing progestagenic and antiprogestagenic effects in rabbits (Selye H., Textbook of Endocrinology, 1947, pp. 345-346), progesterone produces a maximum McPhail score of 4 (by definition). Treatment with a mesoprogesterin in the absence of progesterone leads, however, to a McPhail score which is higher than that under any dose of RU 486, i.e. above 0.5 - 1.0, preferentially 2.0 - 3.0, but to distinctly lower score than 4 at the plateau of the dose response curve at the clinically relevant doses for the claimed indications (i.e. 0.01 mg – 30 mg/rabbit).

The capacity of mesoprogestins to antagonize progesterone function is also tested in the McPhail test using a progesterone dose which induces a McPhail score ranging between 3 and 4. A mesoprogesterin inhibits the effect of progesterone to a significant degree, but the maximum inhibition is below that which is inducible with RU 486 or other pure antiprogestins (e.g. onapristone).

The mesoprogestins stabilize, therefore, the function of PR at an intermediate activity level providing the rationale for the novel clinical applications in gynecological therapy.

Corresponding functional states cannot be achieved with progestins or antiprogestins.

Pharmacological results demonstrating the utility of the mesoprogestins in the claimed indications

The PR antagonistic and agonistic properties of mesoprogestins were assessed in estrogen-primed rabbits in the McPhail test according to Selye (Textbook of Endocrinology, 1947, pp. 345-346).

A) Assessment of PR agonistic properties of mesoprogestins in rabbits (Figure 1 A)

The progestagenic activity of J867, J956, J1042 and RU 486 (dose range: 0.003-100 mg/rabbit) was evaluated in estradiol-primed juvenile rabbits after 4 days of subcutaneous

(s.c.) treatment in the absence of progesterone). The progestagenic effect of the mesoprogestins was observed at doses equal to or higher than 0.03 mg/rabbit. Progesterone induced endometrial transformation at doses equal to or higher than 0.1 mg reaching a maximum effect at 1 mg/rabbit (approximately McPhail score 4). Neither mesoprogesterone tested (J1042, J867, J956) reached the maximum effect of progesterone. J956 showed a biphasic response in this test with a maximum effect of McPhail score 1.5 at 0.3-1 mg/rabbit.

B) Assessment of PR antagonistic properties of mesoprogestins in rabbits (Figure 1B)

Similarly, the antiprogestagenic activity of J867, J956, J1042 and RU 486 (dose range: 0.001-100 mg/rabbit) was evaluated in estradiol-primed juvenile rabbits after 4 days of subcutaneous (s.c.) treatment in the presence of progesterone (1 mg/rabbit s.c.). The first antiprogestagenic effect of the mesoprogestins and RU 486 was observed with a dose of 0.3-1 mg mg/rabbit (McPhail index 0 = no transformation; 4 = complete transformation). The antiprogestagenic activity of mesoprogestins at higher clinically relevant doses (i.e. 3-30 mg/rabbit) was lower than that of RU 486.

In the guinea pig model which allows a good prediction of the effects in humans with respect to the abortifacient activity (Elger W, Beier S., Chwalisz K, Fähnrich M, Hasan SH, Henderson D, Neef G, Rohde R (1986): Studies on the mechanism of action of progesterone antagonists. *J Steroid Biochem* 25: 835-845) the mesoprogestins J 867, J 912, J 956, J 1042 lead up to 100 mg/kg/day to a maximal abortion rate of 20%.

The presence of agonistic activity at the progesterone receptor is beneficial with respect to endometrial protection, i.e. prevention of endometrial hyperplasia due to unopposed estrogen effect on endometrium. Signs of endometrial hyperstimulation were previously described after prolonged treatment of endometriosis with RU 486 (Murphy AA, Kettel LM, Morales AJ, et al., (1995) Endometrial effects of long-term, low-dose administration of RU 486, *Fertil. Steril.* 63: 761-766).

C) Evaluation of abortifacient effects

Physiological background:

The guinea pig is considered as relevant model of human gestation and parturition (Elger W, Fähnrich M, Beier S, Quing SS, Chwalisz K (1987). Endometrial and myometrial effects of

progesterone antagonists in pregnant guinea pigs. *Am J Obstet Gynecol* 157: 1065-1074; Elger W, Neef G, Beier S, Fähnrich M, Gründel M, Heermann J, Malmendier A, Laurent D, Puri CP, Singh MM, Hasan SH, Becker H (1992). Evaluation of antifertility activities of antigestagens in animal model. In: Puri CP and Van Look PFA (eds), *Current Concepts in Fertility Regulation and Reproduction*. Wiley Eastern Limited, New Delhi, pp. 303-328; Elger W, Faehnrich M, Beier S, Qing SS, Chwalisz K (1986). Mechanism of action of progesterone antagonists in pregnant guinea pigs. *Contraception* 6: 47-62; Elger W, Chwalisz K, Faehnrich M, Hasan SH, Laurent D, Beier S, Ottow E, Neef G, Garfield RE (1990). Studies on labor-conditioning and labor-inducing effects of antiprogestones in animal model. In: Garfield RE (eds), Norwell, pp. 153-175.) The mechanism of abortion of antiprogestins in this species is the initiation of labor and finally the expulsion of the conceptus. Abortifacient effects in the rat during very early pregnancy reflect inhibitory effects on nidation rather than initiation of uterine contractions. Studies in the rat model lead to "overestimation" of the potential of antiprogestins to terminate pregnancy in humans. Conversely, in the guinea pig model, irrespective of the antiprogestin doses, there were high rates of ongoing pregnancies similar to the situation in humans (Elger et al., *Current Concepts in Fertility Regulation and Reproduction cited above*). Furthermore, in both humans and guinea pigs, there is a strong synergism between antiprogestins and prostaglandins with respect the induction of labor (see the articles cited above and Elger W, Beier S (1983). Prostaglandine und Antigestagene für den Schwangerschaftsabbruch (Prostaglandins and antigestagens for pregnancy termination). *German Patent DE 3337450* 12; Van Look P, Bygdeman M (1989). Antiprogestational steroids: a new dimension in human fertility regulation. *Oxford reviews of reproductive medicine* 11: 2-60).

Assessment of labor inducing activity: Figure 2.

Pregnant guinea pigs were treated on days 43 and 44 of pregnancy and observed until day 50 of gestation. For the effects of various treatments see table 1 and figure 2. It is typical for this model that expulsions occur with a delay of several days after treatment. It can be seen that Mesoproggestins have a much reduced abortifacient activity compared to RU486. The following ranking of abortifacient activity was found: RU486>J956>J867, J912>J1042. The differences with respect to abortifacient activity seem qualitative ones. It is not possible to overcome the low abortifacient activity of a Mesoproggestin by the use of a higher dose.

Table 1: Studies of relative binding activity (RBA) and ED₅₀ of abortifacient activity in pregnant rats and guinea pigs.

compound	<u>RBA (%) #</u>		abortifacient activity ED ₅₀ (mg/animal/day, s.c.)	
	PR ¹	GR ²	rat ³	guinea pig ⁴
<u>RU 486</u>	506	685	0.98*	3.8
<u>Onapristone</u>	22	39	1.71*	ca 3
J867	302	78	0.65*	>100
J956	345	154	0.64*	20
J912	162	16	0.36	> 100
J1042	164	42	> 10	>> 100

by Kaufmann; ¹progesterone = 100%, ²dexamethasone = 100%

³treatment days 5 – 7 of pregnancy, autopsy day 9, ⁴treatment day 43 – 44 of pregnancy, autopsy day 50, *SAS, probit procedure.

Application forms of the mesoprogestins for the purposes of this invention:

- oral dose range: 0.5 mg/day-100 mg/day
- intramuscular 0.1 mg – 50 mg/day
- intrauterine (IUS), intravaginal (gel, sponge)

Galenical formulation:

Galenical formulations can be provided conventionally, for instance as described in the basic patent applications for the compounds J867, J912, J956 (DE 43 32 283 and DE 43 32 284).

Also, applications can be provided, as known, for transdermal (gel, patch) or intravaginal (gel, suppository) administration

Combinations of the mesoprogestins according to the invention with other pharmacologically active compounds:

Endometriosis and uterine fibroids:

- GnRH-agonists/-antagonist plus mesoprogesterin sequentially (2-3 months GnRH-agonist/antagonist followed by a mesoprogesterin for 3-6 months to maintain the therapeutical effect).
- Combined use of GnRH-agonist/-antagonist for 3-6 months with a mesoprogesterin (add back-therapy) in order to reduce GnRH-induced side effects (hot flushes, osteoporosis).
- The GnRH-agonist/-antagonist for the aforementioned purposes is selected from the group of leuporelin (US 4,005,063), cetorelix (EP 0 299 402 B1), antide WO-A 89/01944), buserelin (GB 1 523 623), ramorelix (EP 0 541 791 A), zoladex (US 4,100,274), 2-(4-acetylamino-phenyl)-4,7-dihydro-7-(2-methoxybenzyl)-3-(N-methyl-N-benzylaminomethyl)-4-oxothieno[2,3-b]-pyridin-5-carbonic acid ethyl ester (WO-A 95/28405), 5-benzoyl-7-(2,6-difluorobenzyl)-4,7-dihydro-3-(N-methyl-N-benzylaminomethyl)-2-(4-propionylamidophenyl)-4-oxothieno[2,3-b]-pyridine and Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂ (WO-A 92/20711).

Dysfunctional bleeding:

- Combination with cyclooxygenase inhibitors (e.g. mefenamic acid, aspirin)
- Combination with an antifibrinolytic agent (e.g. tranexamic acid)

Dysmenorrhea

- Combination with cyclooxygenase inhibitors (e.g. mefenamic acid, aspirin)
- Combination with NO donors (e.g. nitroglycerin)

Regimes of application used for the different indications:**endometriosis and uterine fibroids**

- see above under combinations

treatment of dysfunctional uterine bleeding:

- from the onset of bleeding until the cessation of bleeding

prevention of dysfunctional uterine bleeding:

- d1 up to the end of the third month daily (duration 28 to 60 days)

treatment of dysmenorrhoea:

- d1 up to cessation of the symptoms

prevention of dysmenorrhoea:

- from 3 days up to 28 days before beginning of menstruation

Examples:

1. Acute treatment of dysfunctional bleeding with a mesoprogesterin

Women exhibiting menorrhagia or other form of dysfunctional bleeding are treated for 1-10 days with 5-100 mg of J867 until the cessation of treatment.

2. Prevention of dysfunctional bleeding with a mesoprogesterin

Women with menorrhagia or other form of dysfunctional bleeding are treated with 0.5-25 mg J867 starting on the first day of bleeding for 21-60 day.

3. Treatment of endometriosis

Women with endometriosis are treated for 3-6 months with 5-50 mg J 867, During treatment the reduction of pelvic pain was observed

4. Sequential treatment of endometriosis with an LHRH agonist and J867

Women with endometriosis are treated for 2-3 months with an LHRH agonist such as Lupron. After the cessation of LHRH-agonist therapy women are treated for the next 3-6 months with J 867 in order to avoid osteoporosis induced by prolonged treatment with LHRH agonist. During treatment with 5-50 mg J 867 the therapeutic effects of the LHRH-

agonist are maintained. Treatment with J867 does not produce estrogen deficiency, since the plasma estradiol levels are at the level of the follicular phase.

5. Treatment of uterine fibroids

Women with endometriosis are treated for 3-6 months with 5-50 mg J 867, During treatment the reduction of pelvic pain was observed.

The entire disclosure of all applications, patents and publications, cited above or below, and of corresponding provisional application filed as U.S. Serial No. 09/386,141 on August 31, 1999, and converted to provisional by petition of August 29, 2000 is hereby incorporated by reference.

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims:

1. Use of an effective amount of a mesoprogesterin for the treatment of benign hormone dependent gynecological disorders.
2. Use according to claim 1 wherein the gynecological disorder is: Endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorhagia) and dysmenorrhea.
3. Use of an effective amount of a mesoprogesterin for the prevention of benign hormone dependent gynecological disorders.
4. Use according to claim 3 wherein the gynecological disorder is: Postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorhagia) and dysmenorrhea.
5. Use according to anyone of the preceding claims 1 to 4, wherein the daily dose of mesoprogesterin is 0.5 to 100 mg.
6. Use according to claim 5, wherein the daily dose of mesoprogesterin is 5.0 to 50 mg.
7. Use according to claim 6, wherein the daily dose is 10 to 25 mg.
8. Use of J867, J912, J956 and J1042 according to anyone of preceding claims 1 to 7.
9. Pharmaceutical composition containing a GnRH-analog or antagonist and sequentially thereto a mesoprogesterin.
10. Pharmaceutical composition according to claim 9 for the treatment of endometriosis and uterine fibroids.
11. Pharmaceutical composition according to claim 9 or 10, wherein the GnRH-analog or antagonist is selected from the group of leuprorelin, cetorelix, antide, buserelin, ramorelix, zoladex, 2-(4-acetylaminophenyl)-4,7-dihydro-7-(2-methoxybenzyl)-3(N-methyl-N-benzylaminomethyl)-4-oxothieno[2,3-b]-pyridin-5-carbonic acid ethyl ester,

5-benzoyl-7-(2,6-difluorobenzyl)-4,7-dihydro-3-(n-methyl-N-benzylaminomethyl)-2-(4-propionylamidophenyl)-4-oxothieno[2,3-b]-pyridine and Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂ and the mesoprogesterone is selected from the group of J867, J912, J956 and J1042.

Literature

Preston JT, Cameron IT, Adams EJ, Smith SK (1995) Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br. J Obstet Gynecol 102:401-406

Bonnar J, Sheppard BI (1996) Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ 313:579-582

Intercontinental Medical Statistics Ltd. London:IMS,1994

Chwalisz K., Buhimschi I., Garfield R.E. (1996) Role of nitric oxide in obstetrics. Prenat Neonat Med 1,: 292-329.

Dawood MY (1984) Ibuprofen and dysmenorrhea. Am J Med 77: 87

Dawood MY (1985) Etiology and treatment of dysmenorrhoea Semin Reprod Endocrinol 3:283

Dawood MY (1990) Dysmenorrhoea Clin Obstet Gynaecol 33:168

Dawood MY (1985) Overall approach to managing dysmenorrhoea. In Dawood MY, McGuire JL Demers LM, eds. Premenstrual syndrome and dysmenorrhoea. Baltimore: Urban Schwarzenberg, pp: 177

Lundberg T, Bondesson L, Lundstrom V (1985) Relief of primary dysmenorrhoea by transcutaneous electrical nerves stimulation. Acta Obstet Gynaecol Scand 64:491

Pittrof R, Lees C, Thompson C, Martin JF, Campbell S (1996) Glyceryl trinitrate patches reduce pain in women with severe dysmenorrhoea. Brit Med J 312:884



6. Williams, T , Pratt, J H: Endometriosis in 1000 consecutive celiotomies: medicine and management. Am J Obstet Gynecol 129:245 (1977)

8. Redwine D B: The distribution of endometriosis in the pelvis by age groups and fertility. Fertil Steril 47:173 (1987)

9. Houston D E: Evidence for the risk of pelvic endometriosis by age, race and socioeconomic status. *Epidemiol Rev* 6:167 (1984)
11. Chartman, D L, M D: Modern diagnosis of endometriosis state of the art. *J Reproduct Med* 33,11:861 (1988)
67. Dmowski, W P: Endocrine properties and clinical application of danazol. *Fertil Steril* 31:237 (1979)
68. Buttram, V C, Reiter, R C, Ward, S: Treatment of endometriosis with danazol: report of a 6-year prospective study. *Fertil Steril* 43: 3 (1985)
72. Rose, G L, Dowsett, M, Mudge, J E, White, J O, Jeffcoate, S L: 266. The inhibitory effects of danazol, danazol metabolites, gestrinone and testosterone on the growth of human endometrial cells in vitro, item
73. Schriock, E, Monroe, S E, Henzl, M, Jaffe, R B: Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). *Fertil and Steril* 44:5 (1985)
74. Lemay, A, Maheux, R, Huot, C, Blanchet J, Faure, N: Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. *Am J Obstet Gynecol* 158:233 (1988)
75. Cortes-Prieto, J, Lledo, A, Avila, C, Cortes-Garcia, L, D'acunto, A, Luisi, M, Comaru-Schally, A M, Schally, A V: Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. *Int J Fertil* 32,4:290 (1987)
76. Gudmundsson, J A, Ljunghall, S, Bergquist, C, Wide, L, Nillius, S J: Increased bone turnover during gonadotropin releasing hormone superagonist-induced ovulation inhibition. *J Clin Endocrinol Metabol* 65,1: 159 (1987)
77. Steingold, K A, Cedars, M, Lu, J K H, Randle, D, Judd, H L, Meldrum D R: Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. *Obstet Gynecol* 69,3:49 (1987)

Figures 1A and 1B

Progesterone-like (above, Fig. 1A) and progesterone antagonistic (below, Fig. 1B) effects of PR-modulators in the uterus of estrogen primed immature rabbits (McPhail test)






Figure 2: Cumulative rate of abortion until day 50 in guinea pigs treatment on days 43 and 44 of pregnancy by s.c. injection. (#/#) = rate of abortion

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15679 A3

(51) International Patent Classification⁷: **A61K 31/00**,
31/567, 31/4365, 38/08, 38/09, 38/14, A61P 15/00 //
(A61K 31/4365, 31:567) (A61K 38/08, 31:567) (A61K
38/09, 31:567) (A61K 38/14, 31:567)

D-14195 Berlin (DE). SCHUBERT, Gerd [DE/DE];
Kaethe-Kollwitz-Strasse 13, D-07753 Jena (DE).

(21) International Application Number: PCT/US00/23770

(74) Agents: SOPP, John, A. et al.; Millen, White, Zelano &
Branigan, P.C., Arlington Courthouse Plaza 1, Suite 1400,
2200 Clarendon Boulevard, Arlington, VA 22201 (US).

(22) International Filing Date: 31 August 2000 (31.08.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/386,141 31 August 1999 (31.08.1999) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/386,141 (CIP)
Filed on 31 August 1999 (31.08.1999)

Published:
— with international search report

(71) Applicant (*for all designated States except US*):
JENAPHARM GMBH & CO. KG [DE/DE];
Otto-Schott-Strasse 15, D-07745 Jena (DE).

(88) Date of publication of the international search report:
22 November 2001

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CHWALISZ,
Kristof [DE/DE]; Lobber Steig 7a, D-13505 Berlin
(DE). ELGER, Walter [DE/DE]; Schorlemmerallee 12B,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: MESOPROGESTINS FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE DEPENDENT GY-
NECOLOGICAL DISORDERS

(57) Abstract: This present invention disclosed the use of mesoproggestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoproggestin. Mesoproggestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with proggestins or antiproggestins. The daily dose of mesoproggestin is 0.5 to 100 mg, preferably 5.0 to 50 mg and most preferably 10 to 25 mg. J867, J912, J956 and J1042 are the mesoproggestins preferred according to the invention.

WO 01/15679 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/23770

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/00 A61K31/567 A61K31/4365 A61K38/08 A61K38/09
A61K38/14 A61P15/00 //(A61K31/4365,31:567),(A61K38/08,
31:567),(A61K38/09,31:567),(A61K38/14,31:567)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, MEDLINE, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 576 310 A (SCHUBERT GERD ET AL) 19 November 1996 (1996-11-19) abstract column 3, line 37 - line 65 column 6, line 5 - line 9 table 1 column 7, line 26 - line 31 examples 1,2,4 claims ----- -/-	1-8



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

31 July 2001

Date of mailing of the international search report

08/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Cielen, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/23770

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 43 32 283 A (JENAPHARM GMBH) 13 April 1995 (1995-04-13) cited in the application abstract page 3, line 22 - line 42 page 4, line 66 -page 5, line 20 page 8, line 5 - line 7 page 9, line 35 - line 50 example 1 claims 20,23 ---	1-8
X	WO 98 05679 A (UNIV DUKE) 12 February 1998 (1998-02-12) abstract page 4, line 1 - line 19 page 5, line 13 - line 27 page 6, line 2 -page 7, line 9 page 12, line 10 -page 13, line 13 page 29, line 1 - line 20 page 36, line 4 - line 9 claims 1,4,23,27,28,32-34,37-39,43,44 ---	1-7
X	US 5 696 133 A (HAMANN LAWRENCE G ET AL) 9 December 1997 (1997-12-09) abstract column 2, line 31 - line 41 column 12, line 7 - line 16 column 20, line 61 -column 22, line 32 column 25, line 8 -column 27, line 43 table 1 column 240, line 56 - line 65 example 362 claims 1-8 ---	1-7
A	WO 95 20972 A (HAMPTON ROADS MEDICAL COLLEGE) 10 August 1995 (1995-08-10) abstract page 4, line 24 -page 5, line 6 page 7, line 9 -page 8, line 8 page 10, line 3 -page 12, line 17 page 14, line 4 - line 11 claims 1,4,13-16 ---	1-7,9-11
A	WO 97 27863 A (SCHERING AG ;STOECKEMANN KLAUS (DE); MUHN PETER (DE)) 7 August 1997 (1997-08-07) cited in the application abstract page 1, line 5 - line 10 page 2, line 30 -page 3, line 19 page 6, line 11 - line 20 page 7, line 9 - line 10 claims 1-3,13,14 --- -/--	9-11

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/23770

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DE 198 09 845 A (JENAPHARM GMBH) 9 September 1999 (1999-09-09) abstract page 3, line 42 - line 59 page 4, line 63 -page 5, line 1 page 6, line 31 - line 40 page 9, line 17 - line 36 example 3 claims 15,19,20 ----	1-8
P,X	WO 00 42031 A (BAYER AG) 20 July 2000 (2000-07-20) abstract page 1, line 10 - line 11 page 2, line 10 - line 15 page 3, line 23 - line 28 page 4, line 25 - line 29 page 9, line 13 - line 17 page 9, line 36 -page 10, line 19 page 18, line 5 - line 8 page 21, line 19 - line 30 claim 8 ----	1-7,9,10
E	WO 00 66590 A (ZHANG PUWEN ;ZHI LIN (US); FENSOME ANDREW (US); JONES TODD K (US);) 9 November 2000 (2000-11-09) abstract page 1, line 5 - line 7 page 2, line 21 - line 25 page 5, line 20 - line 24 page 6, line 6 - line 21 page 22, line 25 -page 23, line 3 table 1 example 7 claims 1,3 -----	1-7

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Present claims 1-7, 9, 10 relate to compounds which actually are not well-defined. The use of the definitions "a mesoprogesterin" and "a GnRH-analog or antagonist" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search impossible. Moreover, claims 1, 3, 5-8 relate to a disease which actually is not well-defined. The use of the definition "benign hormone dependent gynecological disorders" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the compounds specifically mentioned in claims 8 and 11, and the diseases specifically mentioned in claims 2, 4 and 10.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/23770

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5576310	A	19-11-1996	NONE	
DE 4332283	A	13-04-1995	US 5693628 A AT 156835 T AU 682195 B AU 7035094 A CA 2130516 A CZ 9401970 A DE 59403717 D DK 648778 T EP 0648778 A ES 2108371 T FI 943687 A GR 3025160 T HU 68029 A JP 2753562 B JP 7149789 A KR 175687 B NO 942953 A NZ 264229 A PL 305092 A RU 2137777 C SK 95794 A	02-12-1997 15-08-1997 25-09-1997 30-03-1995 21-03-1995 12-04-1995 18-09-1997 30-03-1998 19-04-1995 16-12-1997 21-03-1995 27-02-1998 29-05-1995 20-05-1998 13-06-1995 01-04-1999 21-03-1995 27-04-1995 03-04-1995 20-09-1999 12-04-1995
WO 9805679	A	12-02-1998	NONE	
US 5696133	A	09-12-1997	AU 717251 B AU 4597796 A BR 9510486 A CA 2208347 A CN 1175247 A CZ 9701761 A EP 1043325 A EP 1043326 A EP 1041071 A EP 1041066 A EP 1043315 A EP 0800519 A HU 78117 A JP 10510840 T NO 972591 A WO 9619458 A NO 20003550 A NO 20003551 A NO 20003552 A US 5696130 A US 5688808 A US 5693646 A US 5688810 A US 5693647 A US 5696127 A US 6093821 A US 5994544 A US 6121450 A	23-03-2000 10-07-1996 02-06-1998 27-06-1996 04-03-1998 16-09-1998 11-10-2000 11-10-2000 04-10-2000 04-10-2000 11-10-2000 15-10-1997 29-11-1999 20-10-1998 14-08-1997 27-06-1996 14-08-1997 14-08-1997 14-08-1997 09-12-1997 18-11-1997 02-12-1997 18-11-1997 02-12-1997 09-12-1997 25-07-2000 30-11-1999 19-09-2000
WO 9520972	A	10-08-1995	US 5681817 A AP 724 A AT 179610 T	28-10-1997 18-01-1999 15-05-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/23770

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9520972 A		AU 689229 B	26-03-1998
		AU 1838695 A	21-08-1995
		BG 62238 B	30-06-1999
		BG 100766 A	30-06-1997
		BR 9506606 A	09-09-1997
		CA 2182183 A	10-08-1995
		CN 1144486 A	05-03-1997
		CZ 9602103 A	14-05-1997
		DE 69509544 D	10-06-1999
		DE 69509544 T	02-09-1999
		DK 785792 T	18-10-1999
		EP 0785792 A	30-07-1997
		ES 2132645 T	16-08-1999
		FI 963036 A	01-08-1996
		GR 3030164 T	31-08-1999
		HU 74622 A	28-01-1997
		JP 3130048 B	31-01-2001
		JP 9508418 T	26-08-1997
		LT 96133 A, B	27-01-1997
		LV 11782 A	20-06-1997
		LV 11782 B	20-12-1997
		MD 1432 B	31-03-2000
		NO 963237 A	25-09-1996
		NZ 281441 A	29-09-1999
		PL 315792 A	09-12-1996
		RU 2110274 C	10-05-1998
		SK 96296 A	09-07-1997
WO 9727863 A	07-08-1997	DE 19604231 A	31-07-1997
		AU 1596997 A	22-08-1997
		BG 102660 A	30-06-1999
		BR 9707210 A	06-04-1999
		CN 1209750 A	03-03-1999
		CZ 9802391 A	11-11-1998
		EP 0877621 A	18-11-1998
		HU 9901288 A	30-08-1999
		JP 2000505422 T	09-05-2000
		NO 983465 A	18-09-1998
		PL 328066 A	04-01-1999
		SK 98798 A	10-03-1999
		TR 9801452 T	21-10-1998
DE 19809845 A	09-09-1999	AU 3406799 A	20-09-1999
		BG 104712 A	28-02-2001
		BR 9908458 A	14-11-2000
		CN 1291990 T	18-04-2001
		WO 9945023 A	10-09-1999
		EP 1060187 A	20-12-2000
		NO 20004362 A	31-10-2000
		TR 200002506 T	21-12-2000
WO 0042031 A	20-07-2000	AU 2708700 A	01-08-2000
WO 0066590 A	09-11-2000	AU 4501800 A	17-11-2000